RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

One of the problems with being on the outs with Psychiatric, is that applying for future AMPA trials with them could be a problem. As an indication, we know ADHD is out for the forseeable future, regardless of the compound. But Schizo and Depression are also under the purview of Psychiatric (Neuro, please correct me if I'm wrong), so getting new trials approved for these might conceivably be tougher than before, regardless of the particular AMPA compound.

A related concern is the potential for heightened tox requirements for CX-701 and future low impacts prior to allowing trials to proceed. One thing Cortex doesn't need right now is having to do a whole new battery of tox tests for CX-701 prior to the FDA allowing human trials.